Testing effectiveness (Phase 2)UnknownNCT05453383
What this trial is testing
Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib
Who this might be right for
Hepatocellular Cancer
Shen Feng 30